Någård, Mats http://orcid.org/0000-0001-9643-1638
Ah-See, Mei-Lin
Strauss, James
Wise-Draper, Trisha
Safran, Howard P.
Nadeau, Laura
Edenfield, William J.
Lewis, Lionel D.
Ottesen, Lone H.
Li, Yan
Mugundu, Ganesh M.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors
https://doi.org/10.1007/s00280-023-04554-3
Funding for this research was provided by:
AstraZeneca
Article History
Received: 15 March 2023
Accepted: 12 June 2023
First Online: 2 July 2023
Declarations
:
: LDL is a consultant to G1 Therapeutics and 7 Hills Pharma LLC. He also received, through an award to his institution, clinical trial funding for this study from AstraZeneca and other similar clinical trial funding support from the following sponsors: Bristol Myers Squibb, Bayer Pharmaceuticals, and AbbVie. WJE is a consultant for Chimerix Corp. MA and MN are employees and shareholders of AstraZeneca. LHO was an employee of AstraZeneca when this study was designed, executed, and reported. LHO is also a shareholder of AstraZeneca. All other authors have declared no conflicts of interest.
: This study was performed in accordance with the ethical principles of the Declaration of Helsinki and is consistent with the International Council for Harmonisation’s Good Clinical Practice, applicable regulatory requirements, and the AstraZeneca policy on bioethics [CitationRef removed].
: The institutional review boards or independent ethics committees of all investigational sites approved the protocol, and all patients provided written, informed consent.